A newly appointed CEO of a European mid–size pharmaceutical company asked Catenion to help him and his management team review the company's strategy to fully exploit the potential of the pipeline and to help strengthen the company’s strategic capabilities.
Bottom-Up: In–depth review of the R&D project portfolio as well as the portfolio of marketed products; based on this review, Catenion projected likely scenarios for top–line and profit development over the next ten years, pointing to a significant shortfall versus the company's published objectives.
In parallel, a review of strengths and weaknesses in the research, clinical, business development, regulatory, health economics and marketing & sales functions.
Top–Down: Preparation of realistic options for the company along the dimensions:
Synthesis: Based on this analysis — which was developed by Catenion together with the leadership team of the company— a number of strategy options emerged, including M&A to enter a new business field, a significant change in the resource split between in–house R&D and in–licensing, a strategic partnership to outsource a large fraction of one of the core functions, as well as a shift in geographic focus. In the ensuing discussion with the management team, the different options and their impact on risk, top–line and profitability were re–discussed in depth. The team felt it wanted to improve performance both in terms of growth and the risk profile of the company. Before deciding on an option and to engage the organisation a strategy conference was held bringing together the top management and talent of the company.